NCT02434445 Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
| NCT ID | NCT02434445 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The University of Hong Kong |
| Condition | Hepatorenal Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2012-06-01 |
| Primary Completion | 2028-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2012-06-01 with a primary completion date of 2028-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.
Eligibility Criteria
Inclusion Criteria: * Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation * Willing to give informed consent Exclusion Criteria: * Patients with co-existing renal diseases
Contact & Investigator
Desmond Yap, MD
PRINCIPAL INVESTIGATOR
The University of Hong Kong
Frequently Asked Questions
Who can join the NCT02434445 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Hepatorenal Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02434445 currently recruiting?
Yes, NCT02434445 is actively recruiting participants. Contact the research team at desmondy@hku.hk for enrollment information.
Where is the NCT02434445 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT02434445 clinical trial?
NCT02434445 is sponsored by The University of Hong Kong. The principal investigator is Desmond Yap, MD at The University of Hong Kong. The trial plans to enroll 100 participants.